Phathom Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-221.2M | $-334.3M | $-201.6M | $-197.7M | $-143.9M | $-129.1M | $-255.1M | $-1.3M |
| Depreciation & Amortization | $633.0K | $795.0K | $575.0K | $620.0K | $521.0K | $323.0K | $8.0K | — |
| Depreciation | — | — | — | $600.0K | $500.0K | $300.0K | $8.0K | $0 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $28.7M | $24.0M | $45.0M | $24.1M | $16.8M | $5.8M | $406.0K | — |
| Net Cash from Operating Activities | $-166.8M | $-266.8M | $-137.6M | $-146.5M | $-148.5M | $-69.7M | $-36.5M | $-1.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $229.0K | $135.0K | $1.6M | $1.0M | $328.0K | $1.0M | $132.0K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-229.0K | $-135.0K | $-1.6M | $-1.0M | $-328.0K | $-1.0M | $-25.3M | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-288.0K | $182.8M | $367.6M | $120.0M | $44.7M | $114.5M | $304.6M | $1.9M |
| Net Change in Cash | $-167.3M | $-84.1M | $228.4M | $-27.5M | $-104.1M | $43.7M | $242.9M | $879.0K |
| Free Cash Flow | $-167.0M | $-266.9M | $-139.2M | $-147.6M | $-148.8M | $-70.7M | $-36.6M | — |